Market cap
--
Revenue (TTM)
--
P/E Ratio
--
P/B Ratio
--
Div. Yield
--
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
--
-
ROE
--
-
ROCE
--
-
Industry P/E
--
-
EV/EBITDA
--
-
Debt to Equity
--
-
Book Value
--
-
EPS
--
-
Face value
--
-
Shares outstanding
--
5 Years Aggregate
CFO
$-249.30 Mln
EBITDA
$-256.16 Mln
Net Profit
$-175.57 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Akili Inc (AKLI)
| -11.3 | 2.7 | 55.0 | -61.1 | -- | -- | -- |
|
BSE Sensex*
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
|---|---|
|
Akili Inc (AKLI)
| -56.5 |
|
S&P Small-Cap 600
| 13.9 |
|
BSE Sensex
| 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout Akili Inc (AKLI)
Akili, Inc., a digital medicine company, develops cognitive treatments through game-changing technologies. The company provides EndeavorRx, a computer-based testing for cognitive dysfunction across several neurology and psychiatry indications,... including attention-deficit hyperactivity disorder, depressive disorder, autism spectrum disorder, multiple sclerosis, and other neuroinflammatory diseases. It also offers selective stimulus management engine mechanism to activate the fronto-parietal cortex area in the brain; body brain trainer for attention, impulsivity, working memory, and goal management; and spatial navigation engine for spatial navigation, memory, and planning and organization. The company was founded in 2011 and is headquartered in Boston, Massachusetts. As of July 1, 2024, Akili, Inc. operates as a subsidiary of Virtual Therapeutics Corp. Read more
-
Co-Founder & Chairman
Dr. Walter Edward Martucci II, Ph.D.
-
Co-Founder & Chairman
Dr. Walter Edward Martucci II, Ph.D.
-
Headquarters
Boston, MA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Akili Inc (AKLI)
What is the current share price of Akili Inc (AKLI) Today?
The share price of Akili Inc (AKLI) is $0.43 (NASDAQ) as of 02-Jul-2024 09:30 EDT. Akili Inc (AKLI) has given a return of -61.08% in the last 1 years.
What is the current PB & PE ratio of Akili Inc (AKLI)?
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2023 |
-0.64 |
0.65 |
2022 |
-4.22 |
0.30 |
2021 |
-- |
-- |
2020 |
-- |
-- |
2019 |
-- |
-- |
What is the 52 Week High and Low of Akili Inc (AKLI)?
The 52-week high and low of Akili Inc (AKLI) are Rs -- and Rs -- as of 01-Sep-2026.
What is the market cap of Akili Inc (AKLI)?
Akili Inc (AKLI) has a market capitalisation of $ 34 Mln as on 16-Jul-2024. As per SEBI classification, it is a Small Cap company.
Should I invest in Akili Inc (AKLI)?
Before investing in Akili Inc (AKLI), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.